original article Is insulin the most effective injectable antihyperglycaemic therapy?
|
|
- Timothy Sparks
- 5 years ago
- Views:
Transcription
1 Diabetes, Obesity and Metabolism 17: , The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. Is insulin the most effective injectable antihyperglycaemic therapy? J. B. Buse 1,A.Peters 2, D. Russell-Jones 3,S.Furber 4,M.Donsmark 5, J. Han 6, L. MacConell 6,, D. Maggs 6, &M.Diamant 7, 1 University of North Carolina School of Medicine, Medicine/Endocrinology, Chapel Hill, NC, USA 2 Keck School of Medicine, University of Southern California, Los Angeles, CA, USA 3 Endocrinology and Metabolism, Royal Surrey County Hospital, Guildford, UK 4 Novo Nordisk Pharmaceuticals, Sydney, Australia 5 Novo Nordisk A/S, Søborg, Denmark 6 Amylin Pharmaceuticals LLC, San Diego, CA, USA 7 VU University Medical Center, Diabetes Center, Department of Internal Medicine, Amsterdam, The Netherlands ORIGINAL ARTICLE Aims: The recent type 2 diabetes American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) position statement suggested insulin is the most effective glucose-lowering therapy, especially when glycated haemoglobin (HbA1c) is very high. However, randomized studies comparing glucagon-like peptide-1 receptor agonists (GLP-1RAs) exenatide once-weekly [OW; DURATION-3 (Diabetes therapy Utilization: Researching changes in A1c, weight, and other factors Through Intervention with exenatide ONce-Weekly)] and liraglutide once-daily [OD; LEAD-5 (Liraglutide Effect and Action in Diabetes)] with insulin glargine documented greater HbA1c reduction with GLP-1RAs, from baseline HbA1c 8.3% (67mmol/mol). This post hoc analysis of DURATION-3 and LEAD-5 examined changes in HbA1c, fasting glucose and weight with exenatide OW or liraglutide and glargine, by baseline HbA1c quartile. Methods: Descriptive statistics were provided for change in HbA1c, fasting glucose, weight, and insulin dose, and subjects (%) achieving HbA1c <7.0%, by baseline HbA1c quartile. Inferential statistical analysis on the effect of baseline HbA1c quartile was performed for change in HbA1c. An analysis of covariance (ANCOVA) model was used to evaluate similarity in change in HbA1c across HbA1c quartiles. Results: At 26 weeks, in both studies, HbA1c reduction, and proportion of subjects reaching HbA1c <7.0%, were similar or numerically greater with the GLP-1RAs than glargine for all baseline HbA1c quartiles. Fasting glucose reduction was similar or numerically greater with glargine. Weight decreased with both GLP-1RAs across all quartiles; subjects taking glargine gained weight, more at higher baseline HbA1c. Adverse events were uncommon although gastrointestinal events occurred more frequently with GLP-1RAs. Conclusions: HbA1c reduction with the GLP-1RAs appears at least equivalent to that with basal insulin, irrespective of baseline HbA1c. This suggests that liraglutide and exenatide OW may be appropriate alternatives to basal insulin in type 2 diabetes, including when baseline HbA1c is very high ( 9.0%). Keywords: basal insulin, exenatide, GLP-1 receptor agonists, HbA1c, liraglutide Date submitted 14 May 2014; date of first decision 7 July 2014; date of final acceptance 12 October 2014 Introduction The American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) position statement on management of hyperglycaemia in type 2 diabetes designates insulin as the only antihyperglycaemic agent with highest efficacy for reduction of glycated haemoglobin A1c (HbA1c), an index of average glycaemia over the preceding 2 4 months [1]. Correspondence to: Dr J. B. Buse, Endocrinology and Metabolism, University of North Carolina School of Medicine, CB #7172, 8027 Burnett-Womack Building, Chapel Hill, NC , USA. jbuse@med.unc.edu Employed by Amylin LLC, a completely owned subsidiary of Bristol-Myers Squibb, at the time of writing this article. Michaela Diamant died in April 2014, but was completely involved in the preparation and submission of this article. This is an open access article under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Thisopinionwasbasedontheperceptionthatinpatientspresenting with high baseline HbA1c insulin is uniquely effective because of its limitless titration potential. However, studies of the glucagon-like peptide 1 receptor agonists (GLP-1RA) liraglutide and exenatide once-weekly (OW) showed that these GLP-1RAs are superior to insulin glargine with respect to HbA1c reduction [2,3]. However, because the average HbA1c in the populations studied was in the low 8% range, this leaves open the possibility that the overall result did not adequately reflect the effects of these agents in subjects with high baseline values, for example HbA1c >9%,inwhomthetheoretically infinite titration of insulin might prove advantageous. A study group was formed in 2012 to engage the manufacturersofmarketedglp-1rasinacollaborativeefforttoprovide further clarity on the relative efficacy and safety of basal insulin and GLP-1RAs with respect to HbA1c reduction. Of particular interest was the comparative efficacy of different treatment approaches in patients with high baseline HbA1c, who, if treated according to guidelines, would be candidates for insulin
2 DIABETES, OBESITY AND METABOLISM Table 1. Baseline characteristics of subjects enrolled in DURATION-3 and LEAD-5 trials. Duration-3 Exenatide 2 mg OW (N = 233) Insulin glargine OD (N = 223) LEAD-5 Liraglutide 1.8 mg OD (N = 230) Insulin glargine OD (N = 232) Age (years) 58 (10) 58 (9) 58 (10) 58 (11) Male (%) Body mass index (kg/m 2 ) 32 (5) 32 (5) 30 (5) 30 (5) HbA1c (%) 8.3 (1.1) 8.3 (1.0) 8.3 (0.9) 8.2 (0.9) HbA1c (mmol/mol) Fasting blood glucose (mmol/l)* 9.9 (2.5) 9.7 (2.7) 9.1 (2.1) 9.1 (2.0) Duration of diabetes (years) 8.0 (6.0) 7.8 (6.0) 9.2 (5.8) 9.7 (6.4) Prior therapy (N, %) Single OHA 164 (70) 157 (70) 15 (7) 12 (5) Combination (two) OHA 69 (30) 66 (30) 215 (94) 220 (95) Data are mean (s.d.) unless stated otherwise. HbA1c, glycated haemoglobin; OHA, oral antihyperglycaemic agents; OD, once-daily; OW, once-weekly. *Data are fasting serum glucose in DURATION-3 and fasting plasma glucose in LEAD-5. therapy. Here we report the results of a post hoc analysis of the efficacy and safety of liraglutide and exenatide OW compared to glargine across the spectrum of baseline HbA1c, using data from the previously published, open-label, DURATION-3 [2] and LEAD-5 [3] studies in subjects with type 2 diabetes. Materials and Methods The reader is referred to the previously published DURATION-3 [2] and LEAD-5 [3] reports for details of the respective study methods. In brief, DURATION-3 randomized subjects with suboptimal glycaemic control (HbA1c between 7.1 and 11.0%), despite maximum tolerated doses of metformin with or without a sulphonylurea, to exenatide OW 2mg(n= 233) or glargine (n = 223), for 26 weeks. In LEAD-5, subjects with HbA1c between 7.0 and 10.0% on combination therapy with metformin + sulphonylurea were randomized to liraglutide 1.8 mg OD (n = 232), liraglutide placebo (n = 115) or glargine (n = 234) for 26 weeks. In both trials glargine was titrated to achieve fasting glucose (FG) levels 5.5 mmol/l. For the purposes of this post hoc analysis we compared changes in HbA1c, fasting glucose, body weight, insulin dose and adverse events with long-acting GLP-1RAs and glargine intheduration-3andlead-5trials.thebaselinecharacteristics of subjects in both studies are presented in Table 1. In order to gain further understanding of the effect of baseline HbA1c on treatment outcomes, results were stratified by quartile (Q) of baseline HbA1c (Table 2). To investigate possible treatment interaction with baseline HbA1c quartile, inferential statisticalanalysisontheeffectofbaselinehba1cquartilewas performed only for change in HbA1c because of the fact that thesetwoparametersarehighlycorrelated.safetyanalyseswere carried out on the intent-to-treat (ITT) population, defined as allsubjectswhoreceivedatleastonedoseofstudymedication. Hypoglycaemia was classified as per the original studies and was based on symptoms and/or blood glucose measurement. Major hypoglycaemia comprised a symptomatic episode that required third-party assistance because of severe impairment in consciousness or behaviour. Minor hypoglycaemia was defined as symptomatic self-treated, blood glucose <3.0 mmol/l Table 2. Change in HbA1c from baseline and percentage of subjects reaching target HbA1c <7.0% according to baseline HbA1c quartile in DURATION-3 and LEAD-5. Baseline HbA1c quartile range (%) Estimated LS mean treatment difference (95%CI) in change in HbA1c (GLP-1RA glargine; HbA1c % points) Subjects reaching HbA1c <7% n/n (%) DURATION-3 Exenatide OW Glargine Q ( 0.52, 0.08) 48/56 (86) 39/49 (80) Q ( 0.51, 0.07) 42/55 (76) 34/61 (56) Q ( 0.23, 0.34) 27/60 (45) 26/59 (44) Q ( 0.56, 0.02) 24/61 (39) 10/54 (19) LEAD-5 Liraglutide Glargine Q ( 0.66, 0.06) 52/61 (85) 45/63 (71) Q ( 0.41, 0.19) 32/55 (58) 36/69 (52) Q ( 0.61, 0.08) 19/49 (39) 14/44 (32) Q ( 0.53, 0.11) 16/59 (27) 8/49 (16) ANCOVA, analysis of covariance; HbA1c, glycated haemoglobin. Note that subjects were allocated to HbA1c quartile according to HbA1c value at screening. *ANCOVA analysis with last observation carried forward (LOCF) imputation method. 146 Buse et al. Volume 17 No. 2 February 2015
3 DIABETES, OBESITY AND METABOLISM (DURATION-3) or self-treated plasma glucose <3.1 mmol/l (LEAD-5). Efficacy analyses were carried out on a modified ITT population, defined as all subjects who received at least one dose of study medication and had baseline, and at least one postbaseline, measurement of relevance. A last observation carried forward (LOCF) approach was used where postbaseline data were missing. Data Analysis Subjects in each trial were categorized by baseline HbA1c quartile. Descriptive statistics were provided for change in HbA1c, fasting glucose, body weight and insulin dose, as well as the percentage achievinghba1cgoal of<7.0%, by baseline HbA1c quartile. As the mixed model repeated measures (MMRM) introduced complexity in model converging when multiple interaction terms were included, particularly in light of the relatively small sample size, an alternative analysis of covariance (ANCOVA) model was used to evaluate the similarity in change in HbA1c at the endpoint (LOCF) across baseline HbA1c quartiles. In this model, treatment, baseline HbA1c quartile, country, background oral antihyperglycaemic agent (OHA) stratum (DURATION-3 only) and treatment-by-baseline HbA1c quartile interaction were included as fixed effects, and baseline HbA1c value as a covariate [4]. Data were analysed usingsasprocmixed(sas ; SAS Institute, Cary, NC, USA). These studies are registered with ClinicalTrials.gov, number NCT (DURATION-3) and NCT (LEAD-5). Results Baseline patient characteristics in DURATION-3 and LEAD-5 are published elsewhere [2,3] and summarized in Table 1. Population characteristics including age, body mass index (BMI) and baseline HbA1c were similar in the two studies. OHA therapy differed between studies as all subjects in LEAD-5 received sulphonylureas combined with metformin, whereas this is was only the case for 30% of the DURATION-3 population; the remaining 70% of DURATION-3 subjects received metformin alone. After 26 weeks, HbA1c reduction was significantly greater with exenatide OW than glargine [mean HbA1c at 26 weeks: 6.89 vs. 7.06%; mean change 1.42 vs. 1.25%; least squares (LS) mean treatment difference: 0.17%, P = 0.02; 95%CI: 0.31, 0.02] in DURATION-3. Similarly, HbA1c reduction was significantly greater with liraglutide than glargine (mean HbA1c at 26 weeks: 7.0 vs. 7.2%; mean change 1.33 vs. 1.09%; estimated treatment difference: 0.24% P = 0.002; 95%CI: 0.39, 0.08) in LEAD-5. In the analysis by baseline HbA1c quartile, HbA1c values decreased approximately in parallel across the 26-week study period, with numerically greater reductions in GLP-1RA treatment groups than with glargine in all quartiles, at most timepoints (8, 14, 18, 22 and 26 weeks in DURATION-3; 12, 18 and 26 weeks in LEAD-5; Figure S1, Supporting Information). At 26 weeks, HbA1c reduction was numerically similar or greater, and mean HbA1c tendedtobelower,withtheglp-1rasthanwithglarginein all baseline HbA1c quartiles (Figure 1; includes final HbA1c values at 26 weeks, by quartile). Results from the ANCOVA original article analyses showed no interaction between treatment and baseline HbA1c quartile (DURATION-3, P = 0.37; LEAD-5, P = 0.54), indicating that the estimated treatment differences between the GLP-1RAs and glargine were similar across all quartiles in both trials (Table 2).The proportion of subjects reaching target HbA1c (<7.0%) was numerically similar or greater with theglp-1rasthanwithglargineacrossallbaselinehba1c quartiles (Table 2); as expected, the proportion of subjects that reached the HbA1c target was highest in the lowest quartile of baseline HbA1c. After 26 weeks, fasting serum glucose (FSG) levels decreased to a similar (Q2) or lesser (Q1, Q3, Q4) extent with exenatide OW than glargine (DURATION-3) and fasting plasma glucose (FPG) to a similar (Q1, Q3) or lesser (Q2, Q4) extent with liraglutide than glargine (LEAD-5) across all HbA1c quartiles (Figure 1; includes final FSG values at 26 weeks, by quartile).the time course of fasting glucose reduction was similar across quartiles with the GLP-1RAs and glargine. Body weight decreased in subjects taking the GLP-1RAs across all HbA1c quartiles and increased with glargine (Figure 2; includes final body weight at 26 weeks, by quartile). Body weight gain with glargine tended to increase with increasing baseline HbA1c quartile. Mean daily dose of glargine increased with increasing baseline HbA1c quartile in both studies (Figure S2). Major hypoglycaemia occurred rarely in both trials. In DURATION-3, three events occurred that required assistance from another person, one in a patient taking exenatide OW without sulphonylureas and two in subjects taking glargine. In LEAD-5, there were six major hypoglycaemic events in five subjects taking liraglutide, all of whom were also taking sulphonylureas, and no events with glargine. No major hypoglycaemic events occurred in subjects in Q4. The incidence of minor hypoglycaemia was low with exenatide OW ( events/patient-year in all subjects; and events/patient-year in subjects taking and not taking sulphonylureas, respectively) and liraglutide ( events/patient-year in all subjects). In most instances, the rate of minor hypoglycaemia with both GLP-1RAs was numerically lower than that with glargine in all baseline quartiles (Figure 3). Adverse events (Table 1) occurred with similar frequency in both GLP-1RA groups ( 65 70% of subjects) and insulin groups ( 55 60%) in DURATION-3 and LEAD-5; serious events were reported in 4 8% of subjects across groups. As expected from the mode of action of GLP-1RAs, gastrointestinal adverse events, especially nausea, were more common with these agents than with glargine ( 14 vs. 1%, respectively). Injection site reactions were more common with exenatide OW (13%) than with other treatments ( 2%). Discussion Recent position statements [1] and essentially all texts on the subject suggest that insulin is unique among treatments for type 2 diabetes in its antihyperglycaemic efficacy. As a result, insulin therapy is often recommended in patients with HbA1c levels 9.0% who fail to achieve glycaemic control using other agents [1,5]. The post hoc analysis presented here suggests that the ability of the GLP-1RAs liraglutide and exenatide OW to reduce Volume 17 No. 2 February 2015 doi: /dom
4 DIABETES, OBESITY AND METABOLISM Figure 1. Mean (observed) glycated haemoglobin (HbA1c) reduction (%) (A, B) and fasting glucose reduction (mmol/l) (C, D) from baseline after 26 weeks across baseline HbA1c quartiles in DURATION-3, and LEAD-5 studies. Note: fasting glucose data are serum glucose (FSG) for DURATION-3 and plasma glucose (FPG) for LEAD-5. OW, once-weekly. HbA1c is no less than that of glargine in both head-to-head studies and across the spectrum of baseline HbA1c from 7.0 to 11.0%. Arguably, starting liraglutide or exenatide OW is therefore a reasonable alternative to basal insulin in these patients. Further, if HbA1c targets cannot be met, basal insulin may subsequently be added [6,7]. Additional benefits of a GLP-1RA over basal insulin include body weight loss, as opposed to gain; low rates of hypoglycaemia unless combined with sulphonylurea; easier dose titration driven only by tolerability and the lack of a requirement for self-monitoring of blood glucose. It should, however, be acknowledged that initiating treatment with a GLP-1RA or basal insulin is only a first step towards achieving HbA1c targets. Patients may require additional interventions to achieve their individual glycaemic goals. Clinical trials involving insulin are often criticized for lack of appropriate titration, although trials with varying (forced and non-forced) titration strategies, and a wide range of insulin doses (25 62 IU/day), have resulted in similar HbA1c reductions to those reported here [8 10]. In both studies examined here, basal insulin was increased to reach a fasting glucose target through a combination of patient self-titration and titration by study staff. Nonetheless, the fasting glucose levels achieved in DURATION-3 and LEAD-5 remained considerably higher than goal ( 5.5 mmol/l), limiting the potential for overall Figure 2. Mean (observed) change in body weight (kg) from baseline after 26 weeks, across baseline glycated haemoglobin (HbA1c) quartiles in (A) DURATION-3 and (B) LEAD-5. OW, once-weekly. 148 Buse et al. Volume 17 No. 2 February 2015
5 DIABETES, OBESITY AND METABOLISM original article Figure 3. Rates of minor hypoglycaemia (events/patient-year) across baseline glycated haemoglobin (HbA1c) quartiles. DURATION-3 data are shown (A) separately for all subjects; (B) subjects taking sulphonylurea at baseline (C) and subjects not taking sulphonylurea at baseline. Minor hypoglycaemia was defined as self-treated hypoglycaemia symptoms accompanied by blood glucose <3.0 mmol/l (DURATION-3) or fasting plasma glucose <3.1 mmol/l (LEAD-5). Note that in LEAD-5 all subjects were receiving sulphonylurea (D). OD, once-daily; OW, once-weekly; SU, sulphonylurea. glucose-lowering in the glargine arms of both trials. We believe that this is related to hypoglycaemia or other adverse events of therapy as the investigators were required by protocol to titrate to goal, except as limited by safety concerns. However, the percentage of subjects in the highest HbA1c quartile who achieved HbA1c <7.0% in DURATION-3 and LEAD-5 (19 and 16%, respectively) is much lower than that in a pooled analysis of basal insulin studies in which 41% of subjects with baseline HbA1c of %, and 34% of those with HbA1c >9.5%, reached HbA1c <7.0% [11]. This, along with the modest mean insulin doses at 26 weeks, supports the possibility that insulin titration could have been improved in both GLP-1RA studies. That said, even in the Efficacy Assessment of Insulin Glargine Versus LiraglutidE (EAGLE) trial, in which subjects started with a baseline HbA1c of 9%, very rigorous titration of glargine resulted in no significant difference in the proportion of participants reaching an HbA1c <7% (p = 0.44) [12]. Further, it is worth noting that the dosing simplicity and limited need for titration or glucose monitoring when using GLP-1RAs may provide advantages over basal insulin in managing uncontrolled patients in many clinical practice. Furthermore, although the degree of intervention and level of support in clinical trials generally are greater than in routine clinical practice, some medical practices may be able to achieve better relative performance with insulin glargine than that achieved on average across study sites. In both studies reported here withdrawal rates among GLP-1RA-treated subjects were numerically greater than with glargine, in part related to higher rates of adverse events, particularly of a gastrointestinal nature [2,3]. Rates of hypoglycaemia were similar when basal insulin and GLP1-RAs were added to existing therapy, including sulphonylurea. In subjects previously treated with metformin alone, hypoglycaemia was less common when adding GLP-1RA than glargine. This has implications for the management of uncontrolled hyperglycaemia in the outpatient setting. In our analysis, subjects using GLP-1RAs were able to achieve body weight loss across all glycaemic quartiles. This is an important distinction from basal insulin where we observed body weight gain across all glycaemic quartiles; whether the trend towards greater body weight gain in subjects with higher baseline HbA1c is due to a direct effect of increased insulin, increased calorie intake to mitigate hypoglycaemia or perceived risk thereof, correction of more significant hyperglycaemia or a combination of factors is unclear. There are various limitations to this analysis. First, these data represent post hoc analysis of short-term, open-label clinical trials. The study population was limited to those with type 2 diabetes treated with metformin (with or without sulphonylurea) and screening HbA1c between 7.0 and 11.0%, and excluded those with new-onset diabetes, type 1 diabetes, intercurrent illness or suspected issues with adherence. Extrapolationtootherpopulationsoroveralongertimeperiod should be made with caution. In the general population with HbA1c >9.0%, in whom we are suggesting GLP-1RA treatment could be considered a reasonable alternative to basal insulin therapy, many are treated with other background therapies or have new-onset disease, insulin-deficient diabetes, intercurrent illnessorevenpoorerglycaemiccontrolthaninthesestudies. Furthermore, HbA1c and fasting glucose values in the highest HbA1c quartiles of DURATION-3 and LEAD-5 were not extremely high, and results may be different in patients with HbA1c >11.0% and/or fasting glucose >12mmol/l. Thus, these datamayaddanewperspectiveastherearenorandomized Volume 17 No. 2 February 2015 doi: /dom
6 studies in the recent past that have evaluated the optimal management of poorly controlled outpatients. Second, because of the relatively small number of subjects in each quartile group (n= 44 69), the power to detect treatment difference byquartilewaslimited.thus,whereastheoriginalreportof thecompletedatasetshowedsuperiorityofliraglutideand exenatide OW over glargine in HbA1c reduction, we only can suggest similar HbA1c lowering of the three agents across quartiles, even among those with HbA1c >9%.Furthermore,with only 26 weeks of treatment and observation, these data represent a relatively limited number of patient-years of follow-up; examination of change-over-time graphs (Figure S1) show how early discrepancies between groups may even out over time. Third, the resources available when managing subjects in clinical trials are generally more robust than those available in clinical practice. This analysis did not address the resource implications of the two treatment strategies examined and such an evaluation would be worthwhile. We would counsel clinicians who are considering the use of GLP-1RAs instead of basal insulin in patients with HbA1c >9.0% to provide comprehensive patient education; important points to address include potential deterioration of control despite intervention and the need to call or return to clinic if adverse events arise or glycaemia does not improve relatively quickly and consistently. Importantly, we do not intend these post hoc data be used to change policy but rather to alert clinicians to the fact that the long-held belief that insulin is the only appropriate treatment for poorly controlled diabetes may not be supported by current data from trials involving novel agents. Conclusion This post hoc analysis shows similar or numerically greater HbA1c reduction with GLP-1RA as compared to glargine in people with type 2 diabetes, even at baseline HbA1c levels as high as 11.9%. Although data are derived from two different clinical trials involving two long-acting GLP-1RAs, the resultsareremarkablysimilar.thissuggeststhatglp-1rasand insulin may both be appropriate initial treatment choices in selected patients with type 2 diabetes and HbA1c levels above 9.0% despite treatment with oral agents. Acknowledgements Henrik Thomsen of Novo Nordisk is thanked for statistical analyses of LEAD-5. Esther Nathanson, Watermeadow Medical, Witney, UK, funded by Novo Nordisk A/S, is thanked for her contributions to drafting and editing this manuscript under guidance from the authors. Conflict of Interest J. B. B. is an investigator and/or consultant without any direct financial benefit under contracts between his employer and the following companies: Amylin Pharmaceuticals, Inc., Andromeda, AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Dance Biopharm, Elcelyx DIABETES, OBESITY AND METABOLISM Therapeutics Inc., Eli Lilly and Company, GI Dynamics, GlaxoSmithKline, Halozyme Therapeutics, F. Hoffmann-La Roche Ltd., Intarcia Therapeutics, Johnson & Johnson, Lexicon, LipoScience, Medtronic, Merck, Metavention, Novo Nordisk, Orexigen Therapeutics Inc., Osiris Therapeutics Inc., Pfizer Inc., PhaseBio Pharmaceuticals Inc, Quest Diagnostics, Sanofi, Santarus, Scion NeuroStim, Takeda, ToleRx and TransTech Pharma. J. B. B. is a consultant to PhaseBio Pharmaceuticals Inc and has personally received stock options and payments for that work. A. P. has served as a speaker and/or consultant for Abbott, Amylin, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dexcom, Genetech, Janssen, Lifescan, Lilly, Medtronic, Merck, Novo Nordisk, Roche, Sanofi, Takeda. M. D. is a shareholder and employee of Novo Nordisk. S. F. is a shareholder and employee of Novo Nordisk. J. H. is a full-time employee of Amylin Pharmaceuticals, LLC, and a fully owned subsidiary of Bristol-Myers Squibb. L. M. and D. M. were full-time employees of Amylin LLC, a fully owned subsidiary of Bristol-Myers Squibb, at the time of writing this article. M. Di. was consultant for Abbott Diabetes Care, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Poxel Pharma and Sanofi; wasspeakerforaz-bms,elililly,mercksharp&dohme, Novo Nordisk and Sanofi. Through M. Di., the VU University Medical Centre received research grants from Amylin/BMS, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi. M. Di. received no personal payments in connection to the above-mentioned activities, but all paymentsweredirectlytransferredtothenon-profitinstitutional Research Foundation. M. Di. and D. R-.J. were signatory investigators for the DURATION-3 and LEAD-5 studies, respectively. All authors had complete access to primary data for both DURATION-3 and LEAD-5 studies and provided input on content and publication submission. J. H. and Henrik Thomsen (see Acknowledgement) performed analyses for DURATION-3 and LEAD-5, respectively. All authors contributed to developing the analysis plan, data interpretation, writing and editing of the manuscript and approved the final manuscript. Sponsors were involved in the study design, protocol development, collection, review, and analysis of the data and writing of the report. J. B. B. and M. Di. had final responsibility for the decision to submit for publication. Supporting Information Additional Supporting Information may be found in the online version of this article: Figure S1. Mean glycated haemoglobin ± standard mean error (HbA1c ± s.e.m.) over time according to treatment and baseline HbA1c quartile in (A) DURATION-3 and (B) LEAD-5. OD, once-daily; OW, once-weekly. Figure S2. Final daily insulin glargine dose ± standard deviation (s.d.) (IU) after 26 weeks, across baseline glycated haemoglobin (HbA1c) quartiles for (A) DURATION-3 and (B) LEAD-5. Table S1. Adverse events occurring overall and among 5% of subjects enrolled in DURATION-3 and LEAD-5 studies. 150 Buse et al. Volume 17 No. 2 February 2015
7 DIABETES, OBESITY AND METABOLISM References 1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: Russell-Jones D, Vaag A, Schmitz O et al., Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+ SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial. Diabetologia 2009; 52: Qu Y. Issues for stratified randomization based on a factor derived from a continuous baseline variable. Pharm Statist 2011; 10: Handelsman Y, Mechanick JI, Blonde L et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17(Suppl. 2): Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin 2014; 30: original article 7. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014; DOI: /S (14) Yki-Järvinen H, Juurinen L, Alvarsson M et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: Riddle M, Vlajnic A, Zhou R, Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab 2013; 15: Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE). Available from URL: clinicaltrials.gov/ct2/show/nct Accessed 22 September Volume 17 No. 2 February 2015 doi: /dom
Early treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationABSTRACT. uncontrolled on basal insulin? OADs;
Diabetes Ther (2017) 8:673 682 DOI 10.1007/s13300-017-0252-9 BRIEF REPORT Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationiglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:373 382 https://doi.org/10.1007/s13300-017-0336-6 BRIEF REPORT iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationGlucagon-Like Peptide-1 (GLP-1) Agonists
Glucagon-Like Peptide-1 (GLP-1) Agonists Policy Number: 5.01.565 Last Review: 07/2018 Origination: 06/2014 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationFaculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI
Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationBedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:2155 2162 https://doi.org/10.1007/s13300-018-0507-0 BRIEF REPORT Bedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L Ariel Zisman.
More informationS. W. Park 1, W. M. W. Bebakar 2, P. G. Hernandez 3, S. Macura 4, M. L. Hersløv 5 and R. de la Rosa 6. Abstract. Introduction
DIABETICMedicine Research: Treatment Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST â : SIMPLE USE) S. W. Park 1, W. M. W.
More informationABSTRACT BRIEF REPORT
Diabetes Ther (2016) 7:583 590 DOI 10.1007/s13300-016-0179-6 BRIEF REPORT Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition
More informationQuando l insulina basale non basta più: differenti e nuove strategie terapeutiche
Quando l insulina basale non basta più: differenti e nuove strategie terapeutiche Giorgio Sesti Università Magna Graecia di Catanzaro Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di
More informationOriginal Article ABSTRACT
Original Article Allen B. King, MD, FACP, FACE 1 ; Eduard Montanya, MD, PhD 2 ; Richard E. Pratley, MD 3 ; Lawrence Blonde, MD, FACP, FACE 4 ; Claus Bo Svendsen, MD, PhD 5 ; Morten Donsmark, PhD 5 ; Giorgio
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationNEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes
NEWS BRIEFING Adjunctive Therapies in Type 1 and Type 2 Diabetes Moderated by: Bernard Zinman, MD, CM, FRCPC, FACP Lunenfeld-Tanenbaum Research Institute and University of Toronto Mount Sinai Hospital
More informationoriginal article Introduction
original article Diabetes, Obesity and Metabolism 17: 1142 1149, 215. 215 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. ORIGINAL ARTICLE Glycaemic control and hypoglycaemia
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationGLP-1 Agonists for Diabetes
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationTarget Audience. approach this patient case scenario, including identifying an
Activity Overview In this case-based webcast, meet LaWanda, a 57-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 8.4%, she is currently taking basal insulin and fast-acting insulin,
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationComparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes
https://helda.helsinki.fi Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes D'Alessio, D. 2015-02 D'Alessio, D, Haering, H -U, Charbonnel,
More informationUse of a basal-plus insulin regimen in persons with type 2 diabetes stratified by age and body mass index: A pooled analysis of four clinical trials
primary care diabetes 10 (2016) 51 59 Contents lists available at ScienceDirect Primary Care Diabetes journal homepage: http://www.elsevier.com/locate/pcd Original research Use of a basal-plus insulin
More informationOpen Access RESEARCH. Kazuhiro Eto 1*, Yusuke Naito 2 and Yutaka Seino 3
DOI 10.1186/s13098-015-0104-6 RESEARCH Evaluation of the efficacy and safety of lixisenatide add on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationCardiovascular Safety of Incretin Based Therapy
Cardiovascular Safety of Incretin Based Therapy John B. Buse, MD, PhD Verne S. Caviness Distinguished Professor Chief, Division of Endocrinology Executive Associate Dean, Clinical Research University of
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace See Important
More informationThe effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes
The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes This trial is conducted in Europe and North America. The
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationSYSTEMATIC REVIEW. Introduction. X. Xue, 1 Z. Ren, 1 A. Zhang, 2 Q. Yang, 3 W. Zhang, 4 F. Liu 1,4
SYSTEMATIC REVIEW Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationHEALTH PROFESSIONAL v SANOFI
CASE AUTH/3062/8/18 HEALTH PROFESSIONAL v SANOFI Toujeo leaflet A consultant physician complained about a six-page A5 gate-folded leavepiece produced by Sanofi. The leavepiece related to Toujeo (insulin
More informationIndividualising Insulin Regimens: Premixed or basal plus/bolus?
Individualising Insulin Regimens: Premixed or basal plus/bolus? Dr. Ted Wu Director, Diabetes Centre, Hospital Sydney, Australia Turkey, April 2015 Centre of Health Professional Education Optimising insulin
More informationDiabetes Care Publish Ahead of Print, published online June 9, 2016
Diabetes Care 1 Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationR. F. Arakaki 1,T.C.Blevins 2,J.K.Wise 3,D.R.Liljenquist 4,H.H.Jiang 5, J. G. Jacobson 5, S. A. Martin 5 & J. A. Jackson 5.
Diabetes, Obesity and Metabolism 16: 510 518, 2014. 2013 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. original article Comparison of insulin lispro protamine suspension
More informationHow much is too much? Outcomes in patients using high-dose insulin glargine
ORIGINAL PAPER How much is too much? Outcomes in patients using high-dose insulin glargine T. Reid, 1 L. Gao, 2 J. Gill, 3 A. Stuhr, 3 L. Traylor, 3 A. Vlajnic, 3 A. Rhinehart 4 1 Mercy Diabetes Center,
More informationSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
More informationpremix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence
Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)
More informationIDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
Diabetes Ther (2015) 6:573 591 DOI 10.1007/s13300-015-0142-y ORIGINAL RESEARCH IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationARTICLE. B. Charbonnel & H. Steinberg & E. Eymard & L. Xu & P. Thakkar & V. Prabhu & M. J. Davies & S. S. Engel
Diabetologia (2013) 56:1503 1511 DOI 10.1007/s00125-013-2905-1 ARTICLE Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy
More informationNEWS BRIEFING Diabetes and Cardiovascular Disease. Moderated by: Robert Eckel, MD University of Colorado
NEWS BRIEFING Diabetes and Cardiovascular Disease Moderated by: Robert Eckel, MD University of Colorado 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in any
More informationINCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
More informationGli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1?
Impatto degli inibitori di SGLT-2 nei pazienti con diabete di tipo 2 Corso SID Hotel Michelangelo, Milano. 26 Giugno 2018 Gli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1? Emanuele
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationInsulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar )
Insulin glargine U300 (Toujeo ) and insulin glargine biosimilar (Abasaglar ) Lead author: Stephen Erhorn Regional Drug & Therapeutics Centre (Newcastle) November 2015 2015 Summary Toujeo uses the same
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationABSTRACT ORIGINAL RESEARCH
Diabetes Ther (2017) 8:101 114 DOI 10.1007/s13300-016-0218-3 ORIGINAL RESEARCH The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled
More informationConvenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy
Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy Xavier Cos Catalonian Health Institute Barcelona, Spain Stewart B. Harris Western University London, ON, Canada Basal Insulin GLP-1
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationA Clinical Context Report
Type 2 Diabetes in Practice An Expert Commentary with Silvio E. Inzucchi, MD A Clinical Context Report Clinical Context: Type 2 Diabetes in Practice Expert Commentary Jointly Sponsored by: and Clinical
More informationEfficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes
https://helda.helsinki.fi Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes Riddle, Matthew C. 2016-04-01 Riddle, M C, Bolli, G B,
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationinsulin degludec (Tresiba ) is not recommended for use within NHS Scotland.
insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationLiraglutide and Glycaemic Outcomes in the LEADER Trial
Diabetes Ther (2018) 9:2383 2392 https://doi.org/10.1007/s13300-018-0524-z ORIGINAL RESEARCH Liraglutide and Glycaemic Outcomes in the LEADER Trial Bernard Zinman. Michael A. Nauck. Heidrun Bosch-Traberg.
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationORIGINAL ARTICLE. Keywords Glucagon-like peptide 1, Japan, Type 2 diabetes mellitus
Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: HIM Revision Log See Important Reminder
More information22 Diabetes Care Volume 38, January 2015
22 Diabetes Care Volume 38, January 2015 CLIN CARE/EDUCATION/NUTRITION/PSYCHOSOCIAL Predictors of Nonsevere and Severe Hypoglycemia During Glucose- Lowering Treatment With Insulin Glargine or Standard
More informationResults of Phase II Studies of Sitagliptin (MK-0431 / ONO-5345) Investigational Treatment for Type 2 Diabetes Presented by Merck & Co., Inc.
Ono Pharmaceutical Co., Ltd., Public Relations Tel: +81-6-6263-5670 June 13, 2005 Banyu Pharmaceutical Co., Ltd., Public Relations Tel: +81-3-5203-8105 Results of Phase II Studies of Sitagliptin (MK-0431
More informationNew Drug Evaluation: lixisenatide injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPROCEEDINGS CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES * Vivian A. Fonseca, MD, FRCP ABSTRACT
CLINICAL RESEARCH AND EXPERIENCE WITH INCRETIN-BASED THERAPIES Vivian A. Fonseca, MD, FRCP ABSTRACT Despite proven lifestyle recommendations and the availability of a range of oral antidiabetic agents,
More informationSummary. Introduction REVIEW ARTICLE. Johan Jendle 1 * George Grunberger 2 Thomas Blevins 3 Francesco Giorgino 4 Ryan T. Hietpas 5 Fady T.
REVIEW ARTICLE DIABETES/METABOLISM RESEARCH AND REVIEWS Diabetes Metab Res Rev 2016; 32: 776 790. Published online 15 May 2016 in Wiley Online Library (wileyonlinelibrary.com).2810 Efficacy and safety
More information23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
More informationAdherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
More informationrazionale della combinazione insulina/glp-1 RAs
Insulina e GLP-1 RAS: insieme o separati? razionale della combinazione insulina/glp-1 RAs Catania Mercure Catania Excelsior 10 ottobre 2017 Andrea Giaccari andrea.giaccari@unicatt.it Centro per le Malattie
More informationEffects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Prediabetes
Diabetes Care Publish Ahead of Print, published online March 23, 2010 Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Prediabetes
More informationA randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide
A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: LA.PST.14 Effective Date: 03.18 Last Review Date: 3.18 Line of Business: Medicaid Revision Log 1Revision Log 1Revision
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationORIGINAL ARTICLE. basal insulin, GLP-1 RAs, glycaemic control, meta-analysis, systematic review, type 2 diabetes
Received: 11 July 2016 Revised: 28 September 2016 Accepted: 3 October 2016 DOI 10.1111/dom.12805 ORIGINAL ARTICLE Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationARTICLE. J. Rosenstock & M. Davies & P. D. Home & J. Larsen & C. Koenen & G. Schernthaner
Diabetologia (2008) 51:408 416 DOI 10.1007/s00125-007-0911-x ARTICLE A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More information